Center for Scientific Review; Notice of Closed Meetings, 7819 [2016-02972]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 30 / Tuesday, February 16, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Advisory Commission on Childhood
Vaccines; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), notice is hereby
given of the following meeting:
Name: Advisory Commission on
Childhood Vaccines (ACCV).
Date and Time: March 3, 2016, 10:00
a.m. to 3:15 p.m. EDT.
Place: Audio Conference Call and
Adobe Connect Pro.
The ACCV will meet on Thursday,
March 3, 2016, from 10:00 a.m. to 3:15
p.m. (EDT). The public can join the
meeting by:
1. (Audio Portion) Calling the
conference phone number 1–800–779–
3561 and providing the following
information:
Leaders Name: Dr. Narayan Nair.
Password: 8164763.
2. (Visual Portion) Connecting to the
ACCV Adobe Connect Pro Meeting
using the following URL: https://
hrsa.connectsolutions.com/accv/ (copy
and paste the link into your browser if
it does not work directly and enter as a
guest). Participants should call and
connect 15 minutes prior to the meeting
in order for logistics to be set up. If you
have never attended an Adobe Connect
meeting, please test your connection
using the following URL: https://
hrsa.connectsolutions.com/common/
help/en/support/meeting_test.htm and
get a quick overview by following URL:
https://www.adobe.com/go/connectpro_
overview. Call (301) 443–6634 or send
an email to aherzog@hrsa.gov if you are
having trouble connecting to the
meeting site.
Agenda: The agenda items for the
March 2016 meeting will include, but
are not limited to, updates from the
Division of Injury Compensation
Programs (DICP), Department of Justice
(DOJ), National Vaccine Program Office
(NVPO), Immunization Safety Office
(Centers for Disease Control and
Prevention), National Institute of
Allergy and Infectious Diseases
(National Institutes of Health) and
Center for Biologics, Evaluation and
Research (Food and Drug
Administration). A draft agenda and
additional meeting materials will be
posted on the ACCV Web site (https://
www.hrsa.gov/vaccinecompensation/
accv.htm) prior to the meeting. Agenda
items are subject to change as priorities
dictate.
VerDate Sep<11>2014
22:15 Feb 12, 2016
Jkt 238001
Public Comment: Persons interested
in providing an oral presentation should
submit a written request, along with a
copy of their presentation to: Annie
Herzog, DICP, Healthcare Systems
Bureau (HSB), Health Resources and
Services Administration (HRSA), Room
8N146B, 5600 Fishers Lane, Rockville,
Maryland 20857 or email: aherzog@
hrsa.gov. Requests should contain the
name, address, telephone number, email
address, and any business or
professional affiliation of the person
desiring to make an oral presentation.
Groups having similar interests are
requested to combine their comments
and present them through a single
representative. The allocation of time
may be adjusted to accommodate the
level of expressed interest. DICP will
notify each presenter by email, mail, or
telephone of their assigned presentation
time. Persons who do not file an
advance request for a presentation, but
desire to make an oral statement, may
announce it at the time of the public
comment period. Public participation
and ability to comment will be limited
to space and time as it permits.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below at
least 10 days prior to the meeting.
FOR FURTHER INFORMATION CONTACT:
Anyone requiring information regarding
the ACCV should contact Annie Herzog,
DICP, HSB, HRSA, Room 8N146B, 5600
Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–6593, or
email: aherzog@hrsa.gov.
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–03015 Filed 2–12–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
PO 00000
Frm 00078
Fmt 4703
Sfmt 9990
7819
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biological Chemistry and
Macromolecular Biophysics.
Date: March 1, 2016.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: David R Jollie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4150,
MSC 7806, Bethesda, MD 20892, (301)–435–
1722, jollieda@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Investigations on Primary Immunodeficiency
Diseases.
Date: March 3, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jin Huang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4095G,
MSC 7812, Bethesda, MD 20892, 301–435–
1230, jh377p@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR
Review: Synthetic Psychoactive Drugs and
Strategic Approaches to Counteract Their
Deleterious Effects.
Date: March 4, 2016.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5178,
MSC 7844, Bethesda, MD 20892–7844, 301–
435–1033, gaianonr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 9, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–02972 Filed 2–12–16; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 81, Number 30 (Tuesday, February 16, 2016)]
[Notices]
[Page 7819]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-02972]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Biological Chemistry and Macromolecular
Biophysics.
Date: March 1, 2016.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: David R Jollie, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4150, MSC 7806, Bethesda, MD
20892, (301)-435-1722, jollieda@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Investigations on Primary Immunodeficiency
Diseases.
Date: March 3, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jin Huang, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4095G, MSC 7812, Bethesda, MD 20892, 301-435-
1230, jh377p@nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Review: Synthetic Psychoactive Drugs and Strategic
Approaches to Counteract Their Deleterious Effects.
Date: March 4, 2016.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Nicholas Gaiano, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5178, MSC 7844, Bethesda, MD
20892-7844, 301-435-1033, gaianonr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 9, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-02972 Filed 2-12-16; 8:45 am]
BILLING CODE 4140-01-P
